Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Esperion Theraptc (NQ: ESPR ) 1.630 -0.050 (-2.98%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2,809,228 Open 1.700 Bid (Size) 1.640 (1) Ask (Size) 1.650 (3) Prev. Close 1.680 Today's Range 1.630 - 1.710 52wk Range 0.7000 - 3.400 Shares Outstanding 28,277,493 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference September 05, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) September 03, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Performance YTD -44.18% -44.18% 1 Month -7.91% -7.91% 3 Month -25.23% -25.23% 6 Month -37.79% -37.79% 1 Year +64.23% +64.23% More News Read More Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference August 26, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 12, 2024 Via InvestorPlace Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket August 12, 2024 Via Benzinga Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update August 12, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) August 07, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion to Report Second Quarter 2024 Financial Results on August 12 July 25, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion to Participate in Upcoming BTIG Biotech Conference July 24, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries July 16, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility June 28, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Wall Street's Top 10 Stock Calls This Week - Saturday, June 22 June 22, 2024 Via Talk Markets Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session June 20, 2024 Via Benzinga Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday June 20, 2024 Via Benzinga Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget June 13, 2024 Via InvestorPlace 3 Penny Stocks to Buy if You Want to Spend Less and Earn More June 11, 2024 Via InvestorPlace Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 10, 2024 Via Benzinga Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday June 07, 2024 Via Benzinga Esperion to Participate in Upcoming June Investor Conferences May 23, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk May 22, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study May 20, 2024 Via Benzinga Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia May 20, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET® May 14, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) May 10, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS May 08, 2024 Via AB Newswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
